EP3250208
7-bensýl-4-(4-(tríflúrmetýl)bensýl)-1,2,6,7,8,9-hexahýdróimídasó[1,2-A]pýrídó[3,4-E]pýrímídín-5(4H)-ón og sölt þar af og notkun þeirra í meðferð
:
EP einkaleyfi í gildi á Íslandi:
29.1.2016:
30.9.2020:
16744237.5
:
22.12.2020:
15.1.2021
:
28.1.2036:
28.1.2026:
31.1.2026
:
7-BENZYL-4-(4-(TRIFLUOROMETHYL)BENZYL)-1,2,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(4H)-ONE AND SALTS THEREOF AND THEIR USE IN THERAPY
29.1.2016
30.9.2020
22.12.2020
15.1.2021
28.1.2026
:
Oncoceutics, Inc.:
3675 Market Street Suite 200, Philadelphia, PA 19104, US
:
STOGNIEW, Martin:
Florida 34202, US
:
ALLEN, Joshua E.:
New Haven, Connecticut 06511, US
:
POTTORF, Richard S.:
Indianapolis, Indiana 46526, US
:
NALLAGANCHU, Bhaskara Rao:
Hillsborough, New Jersey 08852, US
:
OLSON, Gary L.:
Mountainside, New Jersey 07092, US
:
SUN, Yanjun:
Kendall Park, New Jersey 08824, US
:
Novagraaf Brevets:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
:
201562109737 P:
30.1.2015:
US
:
201562148844 P:
17.4.2015:
US
:
201562233757 P:
28.9.2015:
US
:
US2016015817:
29.1.2016
:
A61K 31/519, C07D 471/12
: 6
: 19.1.2021
: 28.1.2022
: Patice ehf.
: 7
: 31.12.2021
: 28.1.2023
: Patice ehf.
: 8
: 3.1.2023
: 28.1.2024
: Árnason Faktor ehf.
: 9
: 4.1.2024
: 28.1.2025
: Árnason Faktor ehf.
: 10
: 8.1.2025
: 28.1.2026
: Árnason Faktor ehf.